Recursion Pharmaceuticals, Inc.
corporate_fare Company Profile
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for RXRX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Annual Report Reveals Deepening Losses, Critical Control Weaknesses, and New $300M Dilutive Offering
- Recursion Achieves First AI-Driven Clinical Validation, Extends Cash Runway to Early 2028
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$74.68M
Net Income
-$644.76M
Diluted EPS
-$1.44
Op. Cash Flow
-$371.81M
Free Cash Flow
-$378.28M
Gross Profit
$3.73M
Operating Income
-$648.13M
Cash & Equivalents
$743.29M
Debt / Equity
0.00×
Net Margin
-8.63×
Shares Outstanding
528.18M sh
Source: 10-K · filed 2026-02-25 · accession 0001601830-26-000039
show_chartPrice Chart
Loading chart...
feed RXRX - Filings & News (Page 2)
RXRX
Feb 25, 2026, 6:33 AM EST
Annual Report Reveals Deepening Losses, Critical Control Weaknesses, and New $300M Dilutive Offering
Price at Filing:
$3.85
Real-time Price:
$2.51
Change:
-$1.34 (-35%)
Market Cap:
$1.527B
RXRX
Feb 25, 2026, 6:31 AM EST
Price at Filing:
$3.77
Real-time Price:
$2.51
Change:
-$1.26 (-33%)
Market Cap:
$1.527B